Nirmatrelvir-Ritonavir Effective For COVID-19 Management In Patients With CKD Or Kidney Failure, Study Finds

Infectious Disease Advisor (3/19, Kuhns) reports a study found that nirmatrelvir-ritonavir “for the treatment of COVID-19 in patients with chronic kidney disease (CKD) or kidney failure is associated with reduced risk for hospitalization, major adverse cardiovascular events (MACE), and mortality.” According to researchers, “subgroup analyses showed that the benefit of nirmatrelvir-ritonavir against hospitalization was significant for patients with predialysis CKD but not for those with kidney failure.” In addition, “further analysis showed nirmatrelvir-ritonavir was significantly associated with reduced risk of mortality within 1 year of COVID-19 diagnosis...with similar treatment benefits observed in patients with predialysis CKD and in those with kidney failure.” The study was published in Open Forum Infectious Diseases.